Sanofi and GSK announced positive results from late-stage clinical trials of a new vaccine, to be named Vidprevtyn, stated media reports.

This is a protein subunit vaccine which uses harmless protein fragments and is administered in two doses, given about three weeks apart. The vaccine’s phase 3 trials recruited over 10,000 adults in the US, Asia, Africa and Latin America. A separate study is evaluating a third dose to be used as a booster.

After administration of two doses to people with no antibodies against the virus, the vaccine was found to be 58% effective at preventing COVID-19 symptoms, 75% effective at preventing moderate or severe COVID-19 and 100% effective against severe COVID-19 disease, including hospitalization… (ET Healthworld – IANS, February 24, 2022)